Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication

Core Insights - The article highlights the significant reduction of parenteral support (PS) ranging from 12% to 37% in an ongoing proof-of-concept study of crofelemer for pediatric patients with intestinal failure [1] - The study addresses the serious toxicities associated with PS, which has a lethal natural history, indicating that reducing PS could potentially extend and save lives [1] Company and Industry Summary - Jaguar Health, Inc. (NASDAQ:JAGX) announced the publication of results from a study on crofelemer in pediatric patients with intestinal failure due to orphan diseases such as short bowel syndrome (SBS-IF) and microvillus inclusion disease (MVID) [1] - The initial results of the study were presented by Dr. Mohamad Miqdady at the NASPGHAN Annual Meeting on November 8, 2025, showcasing the importance of this research in the field of pediatric gastroenterology [1] - The study is being conducted in the UAE and is independent, indicating a focus on innovative treatments for rare diseases affecting children [1]